{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T10:59:56Z","timestamp":1787741996572,"version":"build-2784847793"},"reference-count":136,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100001960","name":"American Society for Radiation Oncology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001960","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007313","name":"University of Texas MD Anderson Cancer Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007313","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008752","name":"American Association of Neurological Surgeons","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008752","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005653","name":"Congress of Neurological Surgeons","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005653","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["practicalradonc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Practical Radiation Oncology"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.prro.2025.05.014","type":"journal-article","created":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T06:01:01Z","timestamp":1750831261000},"page":"451-471","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Radiation Therapy for WHO Grade 4 Adult-Type Diffuse Glioma: An ASTRO Clinical Practice Guideline"],"prefix":"10.1016","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2901-7477","authenticated-orcid":false,"given":"Debra Nana","family":"Yeboa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steve E.","family":"Braunstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alvin","family":"Cabrera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Crago","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evanthia","family":"Galanis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eyas M.","family":"Hattab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dwight E.","family":"Heron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiayi","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle M.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John P.","family":"Kirkpatrick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan P.S.","family":"Knisely","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary Frances","family":"McAleer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"III","given":"Shearwood","family":"McClelland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael T.","family":"Milano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Moliterno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alyx","family":"Porter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristin J.","family":"Redmond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel M.","family":"Trifiletti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Tsien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhanu Prasad","family":"Venkatesulu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yevgeniy","family":"Vinogradskiy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Bradfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-0130-094X","authenticated-orcid":false,"given":"Amanda R.","family":"Helms","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph A.","family":"Bovi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.prro.2025.05.014_bib0001","series-title":"Clinical Practice Guidelines We Can Trust","year":"2011"},{"key":"10.1016\/j.prro.2025.05.014_bib0002","series-title":"Finding What Works in Health Care: Standards for Systematic Reviews","year":"2011"},{"issue":"5","key":"10.1016\/j.prro.2025.05.014_bib0003","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S1470-2045(09)70025-7","article-title":"Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial","volume":"10","author":"Stupp","year":"2009","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1016\/j.prro.2025.05.014_bib0004","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","article-title":"The 2021 WHO Classification of Tumors of the Central Nervous System: a summary","volume":"23","author":"Louis","year":"2021","journal-title":"Neuro Oncol"},{"issue":"23","key":"10.1016\/j.prro.2025.05.014_bib0005","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1001\/jama.2017.18718","article-title":"Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial","volume":"318","author":"Stupp","year":"2017","journal-title":"JAMA"},{"issue":"10172","key":"10.1016\/j.prro.2025.05.014_bib0006","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/S0140-6736(18)31791-4","article-title":"Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG\/NOA-09): a randomised, open-label, phase 3 trial","volume":"393","author":"Herrlinger","year":"2019","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.prro.2025.05.014_bib0007","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.prro.2016.03.007","article-title":"Radiation therapy for glioblastoma: Executive summary of an American Society for Radiation Oncology Evidence-Based Clinical Practice Guideline","volume":"6","author":"Cabrera","year":"2016","journal-title":"Pract Radiat Oncol"},{"issue":"4","key":"10.1016\/j.prro.2025.05.014_bib0008","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1111\/bpa.12832","article-title":"cIMPACT-NOW update 6: new entity and diagnostic principle recommendations of the cIMPACT-Utrecht meeting on future CNS tumor classification and grading","volume":"30","author":"Louis","year":"2020","journal-title":"Brain Pathol"},{"issue":"3","key":"10.1016\/j.prro.2025.05.014_bib0009","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s00401-020-02127-9","article-title":"cIMPACT-NOW update 5: recommended grading criteria and terminologies for IDH-mutant astrocytomas","volume":"139","author":"Brat","year":"2020","journal-title":"Acta Neuropathol"},{"issue":"2","key":"10.1016\/j.prro.2025.05.014_bib0010","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s11060-020-03528-2","article-title":"The prognostic significance of CDKN2A homozygous deletion in IDH-mutant lower-grade glioma and glioblastoma: a systematic review of the contemporary literature","volume":"148","author":"Lu","year":"2020","journal-title":"J Neurooncol"},{"issue":"5","key":"10.1016\/j.prro.2025.05.014_bib0011","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1007\/s00401-018-1913-0","article-title":"cIMPACT-NOW update 3: recommended diagnostic criteria for \"Diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade IV\"","volume":"136","author":"Brat","year":"2018","journal-title":"Acta Neuropathol"},{"issue":"1","key":"10.1016\/j.prro.2025.05.014_bib0012","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1002\/1097-0142(19850701)56:1<41::AID-CNCR2820560108>3.0.CO;2-W","volume":"56","author":"Hatlevoll","year":"1985","journal-title":"Cancer"},{"issue":"15","key":"10.1016\/j.prro.2025.05.014_bib0013","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1056\/NEJMoa065901","article-title":"Radiotherapy for glioblastoma in the elderly","volume":"356","author":"Keime-Guibert","year":"2007","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.prro.2025.05.014_bib0014","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/S1470-2045(12)70164-X","article-title":"Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial","volume":"13","author":"Wick","year":"2012","journal-title":"Lancet Oncol"},{"issue":"11","key":"10.1016\/j.prro.2025.05.014_bib0015","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1056\/NEJMoa1611977","article-title":"Short-Course Radiation plus Temozolomide in Elderly Patients with Glioblastoma","volume":"376","author":"Perry","year":"2017","journal-title":"New England Journal of Medicine"},{"issue":"8","key":"10.1016\/j.prro.2025.05.014_bib0016","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1200\/JCO.2003.10.035","volume":"21","author":"Grossman","year":"2003","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.prro.2025.05.014_bib0017","doi-asserted-by":"crossref","first-page":"218","DOI":"10.3171\/jns.1985.63.2.0218","article-title":"Phase III comparison of BCNU and the combination of procarbazine, CCNU, and vincristine administered after radiotherapy with hydroxyurea for malignant gliomas","volume":"63","author":"Levin","year":"1985","journal-title":"J Neurosurg"},{"issue":"11","key":"10.1016\/j.prro.2025.05.014_bib0018","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1002\/1097-0142(19821201)50:11<2301::AID-CNCR2820501114>3.0.CO;2-J","article-title":"Malignant astrocytoma: hyperfractionated and standard radiotherapy with chemotherapy in a randomized prospective clinical trial","volume":"50","author":"Payne","year":"1982","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.prro.2025.05.014_bib0019","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/j.ijrobp.2004.04.011","article-title":"Randomized comparison of stereotactic radiosurgery followed by conventional radiotherapy with carmustine to conventional radiotherapy with carmustine for patients with glioblastoma multiforme: report of Radiation Therapy Oncology Group 93-05 protocol","volume":"60","author":"Souhami","year":"2004","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"10.1016\/j.prro.2025.05.014_bib0020","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.radonc.2015.11.021","article-title":"Minimizing the uncertainties regarding the effects of delaying radiotherapy for Glioblastoma: A systematic review and meta-analysis","volume":"118","author":"Loureiro","year":"2016","journal-title":"Radiotherapy & Oncology"},{"issue":"5","key":"10.1016\/j.prro.2025.05.014_bib0021","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.3171\/2014.9.JNS14193","article-title":"Survival impact of time to initiation of chemoradiotherapy after resection of newly diagnosed glioblastoma","volume":"122","author":"Sun","year":"2015","journal-title":"Journal of Neurosurgery"},{"issue":"5","key":"10.1016\/j.prro.2025.05.014_bib0022","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1093\/neuros\/nyx497","article-title":"Impact of Timing of Adjuvant Chemoradiation for Glioblastoma in a Large Hospital Database","volume":"83","author":"Osborn","year":"2018","journal-title":"Neurosurgery"},{"issue":"10","key":"10.1016\/j.prro.2025.05.014_bib0023","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma","volume":"352","author":"Stupp","year":"2005","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.prro.2025.05.014_bib0024","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1200\/JCO.2005.00.331","article-title":"Randomized phase II study of temozolomide and radiotherapy compared with radiotherapy alone in newly diagnosed glioblastoma multiforme","volume":"23","author":"Athanassiou","year":"2005","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.prro.2025.05.014_bib0025","doi-asserted-by":"crossref","first-page":"101","DOI":"10.5114\/ninp.2013.34398","article-title":"Efficacy of concomitant and adjuvant temozolomide in glioblastoma treatment. A multicentre randomized study","volume":"47","author":"Szczepanek","year":"2013","journal-title":"Neurol Neurochir Pol"},{"issue":"4","key":"10.1016\/j.prro.2025.05.014_bib0026","article-title":"Temozolomide for high grade glioma","volume":"2013","author":"Hart","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"issue":"8","key":"10.1016\/j.prro.2025.05.014_bib0027","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1093\/neuonc\/nox025","article-title":"Is more better? The impact of extended adjuvant temozolomide in newly diagnosed glioblastoma: a secondary analysis of EORTC and NRG Oncology\/RTOG","volume":"19","author":"Blumenthal","year":"2017","journal-title":"Neuro-Oncology"},{"issue":"12","key":"10.1016\/j.prro.2025.05.014_bib0028","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1093\/neuonc\/noaa107","article-title":"A phase II randomized, multicenter, open-label trial of continuing adjuvant temozolomide beyond 6 cycles in patients with glioblastoma (GEINO 14-01)","volume":"22","author":"Balana","year":"2020","journal-title":"Neuro-Oncology"},{"issue":"8","key":"10.1016\/j.prro.2025.05.014_bib0029","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJMoa1308345","article-title":"Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma","volume":"370","author":"Chinot","year":"2014","journal-title":"New England Journal of Medicine"},{"issue":"8","key":"10.1016\/j.prro.2025.05.014_bib0030","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1308573","article-title":"A randomized trial of bevacizumab for newly diagnosed glioblastoma","volume":"370","author":"Gilbert","year":"2014","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"10.1016\/j.prro.2025.05.014_bib0031","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1093\/neuonc\/noac099","article-title":"Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated MGMT promoter: An international randomized phase III trial","volume":"25","author":"Omuro","year":"2023","journal-title":"Neuro-Oncology"},{"issue":"11","key":"10.1016\/j.prro.2025.05.014_bib0032","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1093\/neuonc\/noac116","article-title":"Phase III trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated MGMT promoter","volume":"24","author":"Lim","year":"2022","journal-title":"Neuro-Oncology"},{"issue":"3","key":"10.1016\/j.prro.2025.05.014_bib0033","doi-asserted-by":"crossref","first-page":"583","DOI":"10.3171\/2008.5.17557","article-title":"Gliadel (BCNU) wafer plus concomitant temozolomide therapy after primary resection of glioblastoma multiforme","volume":"110","author":"McGirt","year":"2009","journal-title":"J Neurosurg"},{"issue":"1","key":"10.1016\/j.prro.2025.05.014_bib0034","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1186\/s13014-022-02141-z","article-title":"Comparative analysis of the prognosis of external beam radiation therapy (EBRT) and EBRT plus brachytherapy for glioblastoma multiforme: a SEER population-based study","volume":"17","author":"Yang","year":"2022","journal-title":"Radiation Oncology"},{"key":"10.1016\/j.prro.2025.05.014_bib0035","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.jocn.2021.08.022","article-title":"Intraoperative radiotherapy for glioblastoma: A systematic review of techniques and outcomes","volume":"93","author":"Ylanan","year":"2021","journal-title":"J Clin Neurosci"},{"issue":"23","key":"10.1016\/j.prro.2025.05.014_bib0036","doi-asserted-by":"crossref","first-page":"2535","DOI":"10.1001\/jama.2015.16669","article-title":"Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial","volume":"314","author":"Stupp","year":"2015","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.prro.2025.05.014_bib0037","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1007\/s11060-017-2601-y","article-title":"Health-related quality of life, cognitive screening, and functional status in a randomized phase III trial (EF-14) of tumor treating fields with temozolomide compared to temozolomide alone in newly diagnosed glioblastoma","volume":"135","author":"Zhu","year":"2017","journal-title":"Journal of Neuro-Oncology"},{"issue":"3","key":"10.1016\/j.prro.2025.05.014_bib0038","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1093\/neuonc\/noac216","article-title":"Palliative care and end-of-life care in adults with malignant brain tumors","volume":"25","author":"Koekkoek","year":"2023","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.prro.2025.05.014_bib0039","first-page":"07","article-title":"Randomized phase III trial of metabolic imaging-guided dose escalation of radio-chemotherapy in patients with newly diagnosed glioblastoma (SPECTRO GLIO trial)","volume":"07","author":"Laprie","year":"2023","journal-title":"Neuro Oncology"},{"issue":"4","key":"10.1016\/j.prro.2025.05.014_bib0040","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1038\/bjc.1991.396","article-title":"A Medical Research Council trial of two radiotherapy doses in the treatment of grades 3 and 4 astrocytoma. The Medical Research Council Brain Tumour Working Party","volume":"64","author":"Bleehen","year":"1991","journal-title":"Br J Cancer"},{"issue":"2","key":"10.1016\/j.prro.2025.05.014_bib0041","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.ijrobp.2015.01.017","article-title":"Hypofractionated versus standard radiation therapy with or without temozolomide for older glioblastoma patients","volume":"92","author":"Arvold","year":"2015","journal-title":"International Journal of Radiation Oncology, Biology, Physics"},{"issue":"9","key":"10.1016\/j.prro.2025.05.014_bib0042","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1200\/JCO.2004.06.082","article-title":"Abbreviated course of radiation therapy in older patients with glioblastoma multiforme: a prospective randomized clinical trial","volume":"22","author":"Roa","year":"2004","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.prro.2025.05.014_bib0043","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.ijrobp.2014.09.013","article-title":"Standard (60 Gy) or short-course (40 Gy) irradiation plus concomitant and adjuvant temozolomide for elderly patients with glioblastoma: a propensity-matched analysis","volume":"91","author":"Minniti","year":"2015","journal-title":"International Journal of Radiation Oncology, Biology, Physics"},{"issue":"35","key":"10.1016\/j.prro.2025.05.014_bib0044","doi-asserted-by":"crossref","first-page":"4145","DOI":"10.1200\/JCO.2015.62.6606","article-title":"International Atomic Energy Agency Randomized Phase III Study of Radiation Therapy in Elderly and\/or Frail Patients With Newly Diagnosed Glioblastoma Multiforme","volume":"33","author":"Roa","year":"2015","journal-title":"Journal of Clinical Oncology"},{"issue":"9","key":"10.1016\/j.prro.2025.05.014_bib0045","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1016\/S1470-2045(12)70265-6","article-title":"Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial","volume":"13","author":"Malmstrom","year":"2012","journal-title":"Lancet Oncol"},{"issue":"32","key":"10.1016\/j.prro.2025.05.014_bib0046","doi-asserted-by":"crossref","first-page":"4085","DOI":"10.1200\/JCO.2013.49.6968","article-title":"Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial","volume":"31","author":"Gilbert","year":"2013","journal-title":"J Clin Oncol"},{"issue":"23","key":"10.1016\/j.prro.2025.05.014_bib0047","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1056\/NEJM198012043032303","article-title":"Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery","volume":"303","author":"Walker","year":"1980","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.prro.2025.05.014_bib0048","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1016\/0360-3016(79)90553-4","article-title":"An analysis of dose-effect relationship in the radiotherapy of malignant gliomas","volume":"5","author":"Walker","year":"1979","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"6","key":"10.1016\/j.prro.2025.05.014_bib0049","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1002\/1097-0142(19830915)52:6<997::AID-CNCR2820520612>3.0.CO;2-2","article-title":"Comparison of postoperative radiotherapy and combined postoperative radiotherapy and chemotherapy in the multidisciplinary management of malignant gliomas. A joint Radiation Therapy Oncology Group and Eastern Cooperative Oncology Group study","volume":"52","author":"Chang","year":"1983","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.prro.2025.05.014_bib0050","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.ijrobp.2008.05.034","article-title":"Phase I three-dimensional conformal radiation dose escalation study in newly diagnosed glioblastoma: Radiation Therapy Oncology Group Trial 98-03","volume":"73","author":"Tsien","year":"2009","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"8","key":"10.1016\/j.prro.2025.05.014_bib0051","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1002\/(SICI)1097-0142(19960415)77:8<1535::AID-CNCR17>3.0.CO;2-0","article-title":"Final report of a phase I\/II trial of hyperfractionated and accelerated hyperfractionated radiation therapy with carmustine for adults with supratentorial malignant gliomas. Radiation Therapy Oncology Group Study 83-02","volume":"77","author":"Werner-Wasik","year":"1996","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.prro.2025.05.014_bib0052","doi-asserted-by":"crossref","first-page":"S22","DOI":"10.1016\/j.ijrobp.2020.07.2109","article-title":"Radiotherapy (RT) Dose-intensification (DI) Using Intensity-modulated RT (IMRT) versus Standard-dose (SD) RT with Temozolomide (TMZ) in Newly Diagnosed Glioblastoma (GBM): Preliminary Results of NRG Oncology BN001","volume":"108","author":"Gondi","year":"2020","journal-title":"International Journal of Radiation Oncology, Biology, Physics"},{"issue":"5","key":"10.1016\/j.prro.2025.05.014_bib0053","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1016\/j.ijrobp.2021.03.032","article-title":"Initial Results of a Phase 2 Trial of 18F-DOPA PET-Guided Dose-Escalated Radiation Therapy for Glioblastoma","volume":"110","author":"Laack","year":"2021","journal-title":"International Journal of Radiation Oncology, Biology, Physics"},{"issue":"1","key":"10.1016\/j.prro.2025.05.014_bib0054","doi-asserted-by":"crossref","first-page":"vdac006","DOI":"10.1093\/noajnl\/vdac006","article-title":"A multi-institutional pilot clinical trial of spectroscopic MRI-guided radiation dose escalation for newly diagnosed glioblastoma","volume":"4","author":"Ramesh","year":"2022","journal-title":"Neuro-oncology Advances"},{"issue":"3","key":"10.1016\/j.prro.2025.05.014_bib0055","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/j.ijrobp.2021.01.033","article-title":"A Phase 2 Study of Dose-intensified Chemoradiation Using Biologically Based Target Volume Definition in Patients With Newly Diagnosed Glioblastoma","volume":"110","author":"Kim","year":"2021","journal-title":"International Journal of Radiation Oncology, Biology, Physics"},{"issue":"16","key":"10.1016\/j.prro.2025.05.014_bib0056","doi-asserted-by":"crossref","first-page":"2563","DOI":"10.1200\/JCO.2005.04.5963","article-title":"Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive partitioning analysis of the EORTC 26981\/22981-NCIC CE3 phase III randomized trial","volume":"24","author":"Mirimanoff","year":"2006","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.prro.2025.05.014_bib0057","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.ijrobp.2010.06.012","article-title":"Validation and simplification of the Radiation Therapy Oncology Group recursive partitioning analysis classification for glioblastoma","volume":"81","author":"Li","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"6","key":"10.1016\/j.prro.2025.05.014_bib0058","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1056\/NEJMra2301292","article-title":"Frailty in Older Adults","volume":"391","author":"Kim","year":"2024","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.prro.2025.05.014_bib0059","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s11060-024-04699-y","article-title":"Impact of frailty on survival glioblastoma, IDH-wildtype patients","volume":"169","author":"Hudelist","year":"2024","journal-title":"J Neurooncol"},{"issue":"25","key":"10.1016\/j.prro.2025.05.014_bib0060","doi-asserted-by":"crossref","first-page":"3457","DOI":"10.1200\/JCO.2011.34.7625","article-title":"Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study","volume":"29","author":"Hurria","year":"2011","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.prro.2025.05.014_bib0061","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1093\/neuonc\/noaa019","article-title":"A phase I\/II trial of 5-fraction stereotactic radiosurgery with 5-mm margins with concurrent temozolomide in newly diagnosed glioblastoma: primary outcomes","volume":"22","author":"Azoulay","year":"2020","journal-title":"Neuro-Oncology"},{"issue":"12","key":"10.1016\/j.prro.2025.05.014_bib0062","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1002\/cncr.34192","article-title":"Accelerated hypofractionated radiation for elderly or frail patients with a newly diagnosed glioblastoma: A pooled analysis of patient-level data from 4 prospective trials","volume":"128","author":"Perlow","year":"2022","journal-title":"Cancer"},{"issue":"8","key":"10.1016\/j.prro.2025.05.014_bib0063","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1093\/neuonc\/noaa033","article-title":"Superiority of temozolomide over radiotherapy for elderly patients with RTK II methylation class, MGMT promoter methylated malignant astrocytoma","volume":"22","author":"Wick","year":"2020","journal-title":"Neuro-Oncology"},{"issue":"10","key":"10.1016\/j.prro.2025.05.014_bib0064","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1093\/neuonc\/noae108","article-title":"No benefit from TMZ treatment in glioblastoma with truly unmethylated MGMT promoter: Reanalysis of the CE.6 and the pooled Nordic\/NOA-08 trials in elderly glioblastoma patients","volume":"26","author":"Hegi","year":"2024","journal-title":"Neuro Oncol"},{"issue":"26","key":"10.1016\/j.prro.2025.05.014_bib0065","doi-asserted-by":"crossref","first-page":"4293","DOI":"10.1200\/JCO.23.00933","article-title":"Practical Assessment and Management of Vulnerabilities in Older Patients Receiving Systemic Cancer Therapy: ASCO Guideline Update","volume":"41","author":"Dale","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.prro.2025.05.014_bib0066","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1186\/s12885-016-2399-6","volume":"16","author":"Navarria","year":"2016","journal-title":"BMC Cancer"},{"issue":"2","key":"10.1016\/j.prro.2025.05.014_bib0067","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s11060-017-2735-y","article-title":"Clinical and dosimetric study of radiotherapy for glioblastoma: three-dimensional conformal radiotherapy versus intensity-modulated radiotherapy","volume":"137","author":"Thibouw","year":"2018","journal-title":"Journal of Neuro-Oncology"},{"issue":"2","key":"10.1016\/j.prro.2025.05.014_bib0068","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/s11060-023-04465-6","article-title":"Impact of boost sequence in concurrent chemo-radiotherapy on newly diagnosed IDH-wildtype glioblastoma multiforme","volume":"165","author":"Kim","year":"2023","journal-title":"Journal of Neuro-Oncology"},{"key":"10.1016\/j.prro.2025.05.014_bib0069","article-title":"Impact of Including Peritumoral Edema in Radiotherapy Target Volume on Patterns of Failure in Glioblastoma following Temozolomide-based Chemoradiotherapy","volume":"7","author":"Choi","year":"2017","journal-title":"Scientific Reports"},{"issue":"1","key":"10.1016\/j.prro.2025.05.014_bib0070","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1093\/nop\/npz024","article-title":"Impact of volume of irradiation on survival and quality of life in glioblastoma: a prospective, phase 2, randomized comparison of RTOG and MDACC protocols","volume":"7","author":"Kumar","year":"2020","journal-title":"Neuro-Oncology Practice"},{"issue":"1","key":"10.1016\/j.prro.2025.05.014_bib0071","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.ijrobp.2018.01.069","article-title":"Effect of Radiation Treatment Volume Reduction on Lymphopenia in Patients Receiving Chemoradiotherapy for Glioblastoma","volume":"101","author":"Rudra","year":"2018","journal-title":"International Journal of Radiation Oncology, Biology, Physics"},{"issue":"2","key":"10.1016\/j.prro.2025.05.014_bib0072","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1093\/neuonc\/noaa182","article-title":"Proton therapy reduces the likelihood of high-grade radiation-induced lymphopenia in glioblastoma patients: phase II randomized study of protons vs photons","volume":"23","author":"Mohan","year":"2021","journal-title":"Neuro-Oncology"},{"issue":"8","key":"10.1016\/j.prro.2025.05.014_bib0073","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1093\/neuonc\/noab040","article-title":"A prospective phase II randomized trial of proton radiotherapy vs intensity-modulated radiotherapy for patients with newly diagnosed glioblastoma","volume":"23","author":"Brown","year":"2021","journal-title":"Neuro-Oncology"},{"issue":"1","key":"10.1016\/j.prro.2025.05.014_bib0074","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s13014-023-02203-w","article-title":"Observation of the delineation of the target volume of radiotherapy in adult-type diffuse gliomas after temozolomide-based chemoradiotherapy: analysis of recurrence patterns and predictive factors","volume":"18","author":"Liu","year":"2023","journal-title":"Radiation Oncology"},{"key":"10.1016\/j.prro.2025.05.014_bib0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2022.11.024","article-title":"Feasibility of clinical target volume reduction for glioblastoma treated with standard chemoradiation based on patterns of failure analysis","volume":"181","author":"Minniti","year":"2023","journal-title":"Radiotherapy & Oncology"},{"issue":"1","key":"10.1016\/j.prro.2025.05.014_bib0076","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s13014-022-02187-z","article-title":"Charged particle therapy for high-grade gliomas in adults: a systematic review","volume":"18","author":"Wang","year":"2023","journal-title":"Radiation Oncology"},{"issue":"3 Suppl","key":"10.1016\/j.prro.2025.05.014_bib0077","article-title":"Quantitative Analyses of Normal Tissue Effects in the Clinic (QUANTEC): an introduction to the scientific issues","volume":"76","author":"Bentzen","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2025.05.014_bib0078","article-title":"Toxicity and Efficacy of Different Target Volume Delineations of Radiotherapy Based on the Updated RTOG\/NRG and EORTC Guidelines in Patients with Grade 3-4 Glioma: A Randomized Controlled Clinical Trial","author":"Qiu","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2025.05.014_bib0079","article-title":"The Definition and Delineation of the Target Area of Radiotherapy Based on the Recurrence Pattern of Glioblastoma After Temozolomide Chemoradiotherapy","volume":"10","author":"Zheng","year":"2020","journal-title":"Frontiers in Oncology"},{"key":"10.1016\/j.prro.2025.05.014_bib0080","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.radonc.2021.02.017","article-title":"What is the role of the subventricular zone in radiotherapy of glioblastoma patients?","volume":"158","author":"Bender","year":"2021","journal-title":"Radiotherapy & Oncology"},{"issue":"1","key":"10.1016\/j.prro.2025.05.014_bib0081","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.prro.2018.06.001","article-title":"Using Smaller-Than-Standard Radiation Treatment Margins Does Not Change Survival Outcomes in Patients with High-Grade Gliomas","volume":"9","author":"Guram","year":"2019","journal-title":"Practical Radiation Oncology"},{"issue":"6","key":"10.1016\/j.prro.2025.05.014_bib0082","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1118\/1.597396","article-title":"ICRU Report 50\u2014Prescribing, Recording and Reporting Photon Beam Therapy","volume":"21","author":"Jones","year":"1994","journal-title":"Medical Physics"},{"issue":"879","key":"10.1016\/j.prro.2025.05.014_bib0083","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1259\/bjr.74.879.740294","article-title":"Prescribing, Recording and Reporting Photon Beam Therapy (Supplement to ICRU Report 50), ICRU Report 62. ICRU, pp. ix+52, 1999 (ICRU Bethesda, MD) $65.00 ISBN 0-913394-61-0","volume":"74","author":"Morgan-Fletcher","year":"2014","journal-title":"British Journal of Radiology"},{"key":"10.1016\/j.prro.2025.05.014_bib0084","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.radonc.2019.06.009","article-title":"Bevacizumab reduces toxicity of reirradiation in recurrent high-grade glioma","volume":"138","author":"Fleischmann","year":"2019","journal-title":"Radiotherapy & Oncology"},{"key":"10.1016\/j.prro.2025.05.014_bib0085","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.radonc.2021.12.019","article-title":"Re-irradiation for recurrent high grade glioma (HGG) patients: Results of a single arm prospective phase 2 study","volume":"167","author":"Navarria","year":"2022","journal-title":"Radiotherapy & Oncology"},{"issue":"6","key":"10.1016\/j.prro.2025.05.014_bib0086","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1200\/JCO.22.00164","article-title":"NRG Oncology\/RTOG1205: A Randomized Phase II Trial of Concurrent Bevacizumab and Reirradiation Versus Bevacizumab Alone as Treatment for Recurrent Glioblastoma","volume":"41","author":"Tsien","year":"2023","journal-title":"Journal of Clinical Oncology"},{"issue":"4","key":"10.1016\/j.prro.2025.05.014_bib0087","doi-asserted-by":"crossref","first-page":"757","DOI":"10.3171\/2014.11.JNS13295","article-title":"Role of adjuvant or salvage radiosurgery in the management of unresected residual or progressive glioblastoma multiforme in the pre-bevacizumab era","volume":"122","author":"Niranjan","year":"2015","journal-title":"Journal of Neurosurgery"},{"issue":"5","key":"10.1016\/j.prro.2025.05.014_bib0088","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1002\/cam4.1425","article-title":"Re-irradiation of recurrent gliomas: pooled analysis and validation of an established prognostic score-report of the Radiation Oncology Group (ROG) of the German Cancer Consortium (DKTK)","volume":"7","author":"Combs","year":"2018","journal-title":"Cancer Medicine"},{"key":"10.1016\/j.prro.2025.05.014_bib0089","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.radonc.2018.10.034","article-title":"Patterns of re-irradiation for recurrent gliomas and validation of a prognostic score","volume":"130","author":"Post","year":"2019","journal-title":"Radiotherapy & Oncology"},{"issue":"5","key":"10.1016\/j.prro.2025.05.014_bib0090","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1093\/nop\/npz017","article-title":"Reirradiation of recurrent high-grade glioma and development of prognostic scores for progression and survival","volume":"6","author":"Chapman","year":"2019","journal-title":"Neuro-Oncology Practice"},{"issue":"4","key":"10.1016\/j.prro.2025.05.014_bib0091","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.adro.2018.06.005","article-title":"Re-irradiation for malignant glioma: Toward patient selection and defining treatment parameters for salvage","volume":"3","author":"Shen","year":"2018","journal-title":"Advances in radiation oncology"},{"key":"10.1016\/j.prro.2025.05.014_bib0092","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.652646","article-title":"CyberKnife for Recurrent Malignant Gliomas: A Systematic Review and Meta-Analysis","volume":"11","author":"De Maria","year":"2021","journal-title":"Frontiers in Oncology"},{"key":"10.1016\/j.prro.2025.05.014_bib0093","article-title":"Brachytherapy is an effective and safe salvage option for re-irradiation in recurrent glioblastoma (rGBM): A systematic review","volume":"190","author":"Xiang","year":"2023","journal-title":"Radiotherapy & Oncology"},{"issue":"3","key":"10.1016\/j.prro.2025.05.014_bib0094","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1159\/000509782","article-title":"Gamma Knife Radiosurgery for High-Grade Gliomas: Single-Center Experience of Six Years in China","volume":"99","author":"Zhao","year":"2021","journal-title":"Stereotactic & Functional Neurosurgery"},{"issue":"4","key":"10.1016\/j.prro.2025.05.014_bib0095","first-page":"281","article-title":"Gamma knife radiosurgery for local recurrence of glioblastoma","volume":"39","author":"Guseynova","year":"2018","journal-title":"Neuroendocrinology Letters"},{"issue":"12","key":"10.1016\/j.prro.2025.05.014_bib0096","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1007\/s00066-018-1358-3","article-title":"CT-guided interstitial HDR-brachytherapy for recurrent glioblastoma multiforme: a 20-year single-institute experience","volume":"194","author":"Chatzikonstantinou","year":"2018","journal-title":"Strahlentherapie und Onkologie"},{"issue":"1","key":"10.1016\/j.prro.2025.05.014_bib0097","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1227\/NEU.0000000000001344","article-title":"Indications and Efficacy of Gamma Knife Stereotactic Radiosurgery for Recurrent Glioblastoma: 2 Decades of Institutional Experience","volume":"80","author":"Imber","year":"2017","journal-title":"Neurosurgery"},{"issue":"8","key":"10.1016\/j.prro.2025.05.014_bib0098","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1007\/s10072-015-2172-7","article-title":"Radiosurgery reirradiation for high-grade glioma recurrence: a retrospective analysis","volume":"36","author":"Pinzi","year":"2015","journal-title":"Neurological Sciences"},{"issue":"5","key":"10.1016\/j.prro.2025.05.014_bib0099","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/j.adro.2020.06.005","article-title":"Reirradiation of High-Grade Gliomas: A Retrospective Analysis of 198 Patients Based on the Charite Data Set","volume":"5","author":"Kaul","year":"2020","journal-title":"Advances in radiation oncology"},{"issue":"3","key":"10.1016\/j.prro.2025.05.014_bib0100","first-page":"199","article-title":"Long-term outcome data from 121 patients treated with Gamma Knife stereotactic radiosurgery as salvage therapy for focally recurrent high-grade gliomas","volume":"6","author":"Smith","year":"2019","journal-title":"Journal of Radiosurgery and SBRT"},{"issue":"7","key":"10.1016\/j.prro.2025.05.014_bib0101","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1007\/s12094-020-02526-0","article-title":"High-dose salvage re-irradiation for recurrent\/progressive adult diffuse glioma: healing or hurting?","volume":"23","author":"Gupta","year":"2021","journal-title":"Clinical & Translational Oncology: Official Publication of the Federation of Spanish Oncology Societes & of the National Cancer Institute of Mexico"},{"issue":"2","key":"10.1016\/j.prro.2025.05.014_bib0102","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s11060-015-1825-y","article-title":"Re-resection for recurrent high-grade glioma in the setting of re-irradiation: more is not always better","volume":"124","author":"Palmer","year":"2015","journal-title":"Journal of Neuro-Oncology"},{"issue":"7","key":"10.1016\/j.prro.2025.05.014_bib0103","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1007\/s00701-021-04794-3","article-title":"Radiotherapy versus combination radiotherapy-bevacizumab for the treatment of recurrent high-grade glioma: a systematic review","volume":"163","author":"Kulinich","year":"2021","journal-title":"Acta Neurochirurgica"},{"key":"10.1016\/j.prro.2025.05.014_bib0104","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctro.2023.100697","article-title":"Re-irradiation of recurrent IDH-wildtype glioblastoma in the bevacizumab and immunotherapy era: Target delineation, outcomes and patterns of recurrence","volume":"44","author":"Christ","year":"2024","journal-title":"Clinical and Translational Radiation Oncology"},{"issue":"3","key":"10.1016\/j.prro.2025.05.014_bib0105","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1007\/s11060-023-04441-0","article-title":"Reirradiation versus systemic therapy versus combination therapy for recurrent high-grade glioma: a systematic review and meta-analysis of survival and toxicity","volume":"164","author":"Marwah","year":"2023","journal-title":"Journal of Neuro-Oncology"},{"key":"10.1016\/j.prro.2025.05.014_bib0106","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2024.110696","article-title":"ESTRO\/EANO recommendation on reirradiation of glioblastoma","volume":"204","author":"Andratschke","year":"2025","journal-title":"Radiotherapy and Oncology"},{"issue":"4","key":"10.1016\/j.prro.2025.05.014_bib0107","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/j.ijrobp.2020.06.020","article-title":"Pulsed Reduced Dose Rate Radiotherapy in Conjunction With Bevacizumab or Bevacizumab Alone in Recurrent High-grade Glioma: Survival Outcomes","volume":"108","author":"Bovi","year":"2020","journal-title":"International Journal of Radiation Oncology, Biology, Physics"},{"issue":"4","key":"10.1016\/j.prro.2025.05.014_bib0108","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1016\/j.ijrobp.2024.01.013","article-title":"Prospective Randomized Phase 2 Trial of Hypofractionated Stereotactic Radiation Therapy of 25 Gy in 5 Fractions Compared With 35 Gy in 5 Fractions in the Reirradiation of Recurrent Glioblastoma","volume":"119","author":"Chen","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"12 Suppl 2","key":"10.1016\/j.prro.2025.05.014_bib0109","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1093\/neuonc\/noad258","article-title":"Evolving concepts in margin strategies and adaptive radiotherapy for glioblastoma: A new future is on the horizon","volume":"26","author":"Tseng","year":"2024","journal-title":"Neuro Oncol"},{"issue":"12","key":"10.1016\/j.prro.2025.05.014_bib0110","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1001\/jamaoncol.2016.6905","article-title":"Using the National Cancer Database for Outcomes Research: A Review","volume":"3","author":"Boffa","year":"2017","journal-title":"JAMA Oncol"},{"issue":"suppl_1","key":"10.1016\/j.prro.2025.05.014_bib0111","doi-asserted-by":"crossref","first-page":"i11","DOI":"10.1093\/jrr\/rrx103","article-title":"Newly diagnosed glioblastoma: adverse socioeconomic factors correlate with delay in radiotherapy initiation and worse overall survival","volume":"59","author":"Pollom","year":"2018","journal-title":"Journal of Radiation Research"},{"issue":"1","key":"10.1016\/j.prro.2025.05.014_bib0112","doi-asserted-by":"crossref","first-page":"vdab040","DOI":"10.1093\/noajnl\/vdab040","article-title":"Impact of race on care, readmissions, and survival for patients with glioblastoma: an analysis of the National Cancer Database","volume":"3","author":"Hodges","year":"2021","journal-title":"Neuro-oncology Advances"},{"issue":"3","key":"10.1016\/j.prro.2025.05.014_bib0113","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s11060-021-03736-4","article-title":"Racial\/ethnic disparities in treatment pattern and time to treatment for adults with glioblastoma in the US","volume":"152","author":"Ostrom","year":"2021","journal-title":"Journal of Neuro-Oncology"},{"issue":"5","key":"10.1016\/j.prro.2025.05.014_bib0114","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1093\/nop\/npaa029","article-title":"Geographic and socioeconomic considerations for glioblastoma treatment in the elderly at a national level: a US perspective","volume":"7","author":"Lu","year":"2020","journal-title":"Neuro-Oncology Practice"},{"issue":"3","key":"10.1016\/j.prro.2025.05.014_bib0115","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1007\/s11060-020-03480-1","article-title":"Geographic disparities in access to glioblastoma treatment based on Hispanic ethnicity in the United States: Insights from a national database","volume":"147","author":"Lu","year":"2020","journal-title":"Journal of Neuro-Oncology"},{"issue":"6","key":"10.1016\/j.prro.2025.05.014_bib0116","doi-asserted-by":"crossref","first-page":"E16","DOI":"10.3171\/2018.3.FOCUS1852","article-title":"Disparities in health care determine prognosis in newly diagnosed glioblastoma","volume":"44","author":"Chandra","year":"2018","journal-title":"Neurosurgical Focus"},{"issue":"2","key":"10.1016\/j.prro.2025.05.014_bib0117","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s11060-018-2875-8","article-title":"Management of glioblastoma at safety-net hospitals","volume":"139","author":"Brandel","year":"2018","journal-title":"Journal of Neuro-Oncology"},{"issue":"20","key":"10.1016\/j.prro.2025.05.014_bib0118","doi-asserted-by":"crossref","first-page":"3157","DOI":"10.1002\/cncr.30160","article-title":"Influence of insurance status on survival of adults with glioblastoma multiforme: A population-based study","volume":"122","author":"Rong","year":"2016","journal-title":"Cancer"},{"key":"10.1016\/j.prro.2025.05.014_bib0119","first-page":"1","article-title":"Insurance type impacts the economic burden and survival of patients with newly diagnosed glioblastoma","author":"Chandra","year":"2019","journal-title":"Journal of Neurosurgery"},{"key":"10.1016\/j.prro.2025.05.014_bib0120","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.wneu.2015.12.081","article-title":"A Modern Radiotherapy Series of Survival in Hispanic Patients with Glioblastoma","volume":"88","author":"Wu","year":"2016","journal-title":"World Neurosurgery"},{"issue":"2","key":"10.1016\/j.prro.2025.05.014_bib0121","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s11060-017-2377-0","article-title":"Incidence, survival, pathology, and genetics of adult Latino Americans with glioblastoma","volume":"132","author":"Shabihkhani","year":"2017","journal-title":"Journal of Neuro-Oncology"},{"issue":"1","key":"10.1016\/j.prro.2025.05.014_bib0122","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s11060-020-03572-y","article-title":"Racial and socioeconomic disparities differentially affect overall and cause-specific survival in glioblastoma","volume":"149","author":"Liu","year":"2020","journal-title":"Journal of Neuro-Oncology"},{"key":"10.1016\/j.prro.2025.05.014_bib0123","doi-asserted-by":"crossref","DOI":"10.1093\/neuonc\/noae165.0582","article-title":"DISP-08. GBM patients face ttf access and information inequity that may impact patient outcomes and quality-of-life","author":"Ostrom","year":"2024","journal-title":"Neuro-Oncology"},{"issue":"1","key":"10.1016\/j.prro.2025.05.014_bib0124","doi-asserted-by":"crossref","first-page":"vdab008","DOI":"10.1093\/noajnl\/vdab008","article-title":"Real-world validity of randomized controlled phase III trials in newly diagnosed glioblastoma: to whom do the results of the trials apply?","volume":"3","author":"Skaga","year":"2021","journal-title":"Neuro-oncology Advances"},{"issue":"Suppl 11","key":"10.1016\/j.prro.2025.05.014_bib0125","doi-asserted-by":"crossref","first-page":"S282","DOI":"10.4103\/2152-7806.181985","article-title":"Socioeconomic status does not affect prognosis in patients with glioblastoma multiforme","volume":"7","author":"Kasl","year":"2016","journal-title":"Surgical neurology international"},{"issue":"1","key":"10.1016\/j.prro.2025.05.014_bib0126","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1093\/nop\/npy014","article-title":"Patterns and disparities of care in glioblastoma","volume":"6","author":"Dressler","year":"2019","journal-title":"Neuro-Oncology Practice"},{"issue":"19","key":"10.1016\/j.prro.2025.05.014_bib0127","doi-asserted-by":"crossref","first-page":"3390","DOI":"10.1002\/cncr.32328","article-title":"Glioma incidence and survival variations by county-level socioeconomic measures","volume":"125","author":"Cote","year":"2019","journal-title":"Cancer"},{"key":"10.1016\/j.prro.2025.05.014_bib0128","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.ejca.2020.12.027","article-title":"Association between socioeconomic status and survival in glioblastoma: An Italian single-centre prospective observational study","volume":"145","author":"Tosoni","year":"2021","journal-title":"European Journal of Cancer"},{"issue":"S1","key":"10.1016\/j.prro.2025.05.014_bib0129","doi-asserted-by":"crossref","first-page":"S72","DOI":"10.2105\/AJPH.2018.304844","article-title":"Structural Interventions to Reduce and Eliminate Health Disparities","volume":"109","author":"Brown","year":"2019","journal-title":"Am J Public Health"},{"issue":"11","key":"10.1016\/j.prro.2025.05.014_bib0130","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1093\/neuonc\/noab172","article-title":"SNO 2020 diversity survey: defining demographics, racial biases, career success metrics and a path forward for the field of neuro-oncology","volume":"23","author":"Chukwueke","year":"2021","journal-title":"Neuro Oncol"},{"issue":"41","key":"10.1016\/j.prro.2025.05.014_bib0131","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1200\/EDBK_320803","article-title":"Delivering Equitable Care to Underserved Neuro-oncology Populations","author":"Porter","year":"2021","journal-title":"American Society of Clinical Oncology Educational Book"},{"issue":"3","key":"10.1016\/j.prro.2025.05.014_bib0132","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1038\/s41416-019-0603-6","article-title":"Circulating biomarkers in patients with glioblastoma","volume":"122","author":"Muller Bark","year":"2020","journal-title":"Br J Cancer"},{"issue":"Supplement_7","key":"10.1016\/j.prro.2025.05.014_bib0133","doi-asserted-by":"crossref","DOI":"10.1093\/neuonc\/noac209.639","article-title":"NIMG-21. Interim analysis of a phase ii study of multiparametric mr-guided high-dose response-adaptive radiotherapy with concurrent temozolomide in patients with newly diagnosed glioblastoma","volume":"24","author":"Kim","year":"2022","journal-title":"Neuro-Oncology"},{"issue":"2, Supplement","key":"10.1016\/j.prro.2025.05.014_bib0134","doi-asserted-by":"crossref","first-page":"S84","DOI":"10.1016\/j.ijrobp.2023.06.406","article-title":"Efficacy and Toxicity of Different Target Volume Delineations of Radiotherapy Based on the Updated RTOG\/NRG and EORTC Guidelines in Patients with High Grade Glioma: A Randomized, Controlled Clinical Trial","volume":"117","author":"Liu","year":"2023","journal-title":"International Journal of Radiation Oncology*Biology*Physics"},{"key":"10.1016\/j.prro.2025.05.014_bib0135","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.jclinepi.2021.03.001","article-title":"The PRISMA 2020 statement: An updated guideline for reporting systematic reviews","volume":"134","author":"Page","year":"2021","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.prro.2025.05.014_bib0136","doi-asserted-by":"crossref","first-page":"n160","DOI":"10.1136\/bmj.n160","article-title":"PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"}],"container-title":["Practical Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879850025001638?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879850025001638?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T14:01:28Z","timestamp":1762783288000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1879850025001638"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":136,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S1879850025001638"],"URL":"https:\/\/doi.org\/10.1016\/j.prro.2025.05.014","relation":{},"ISSN":["1879-8500"],"issn-type":[{"value":"1879-8500","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Radiation Therapy for WHO Grade 4 Adult-Type Diffuse Glioma: An ASTRO Clinical Practice Guideline","name":"articletitle","label":"Article Title"},{"value":"Practical Radiation Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.prro.2025.05.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 American Society for Radiation Oncology. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}